ArticleOncogene2020
Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer.
Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- Cancer-associated alterations in O-GalNAc glycosylation.Glycobiology · 2026Review
- Defective autophagy in GNE myopathy is rescued by inhibition of noncanonical Akt-mTORC1 activation across multiple isogenic models.Experimental & molecular medicine · 2026Article
- Isomeranzin activates Gnas-AMPK signaling to drive white adipose browning and curb obesity in mice.EMBO molecular medicine · 2026Article
- Benchmarking of dimensionality reduction methods to capture drug response in transcriptome data.Scientific reports · 2025Article
- Identification and validation of glycosyltransferase-related gene signatures to predict prognosis and immunological characteristics of renal clear cell carcinoma.Translational andrology and urology · 2025Article
- Integrative transcriptomic analysis identifies emetine as a promising candidate for overcoming acquired resistance to ALK inhibitors in lung cancer.Molecular oncology · 2025Article
- Mechanism of the GALNT family proteins in regulating tumorigenesis and development of lung cancer (Review).Molecular and clinical oncology · 2025Review
- Signature-based repurposed drugs resemble the inhibition of TGFβ-induced NDRG1 as potential therapeutics for triple-negative breast cancer.International journal of biological sciences · 2025Article
- Systematic omics analysis identifies CCR6 as a therapeutic target to overcome cancer resistance to EGFR inhibitors.iScience · 2024Article
- Article
- 5-aminosalicylic acid suppresses osteoarthritis through the OSCAR-PPARγ axis.Nature communications · 2024Article
- Epigenetic repression of CHCHD2 enhances survival from single cell dissociation through attenuated Rho A kinase activity.Cellular and molecular life sciences : CMLS · 2024Article
- Article
- Deep Learning Approach Based on Transcriptome Profile for Data Driven Drug Discovery.Molecules and cells · 2023Article
- Simple, fast, and flexible framework for matrix completion with infinite width neural networks.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- O-Glycosylating Enzyme GALNT2 Predicts Worse Prognosis in Cervical Cancer.Pathology oncology research : POR · 2022Article
- Vessel state and immune infiltration of the angiogenesis subgroup and construction of a prediction model in osteosarcoma.Frontiers in immunology · 2022Article
- Systematic transcriptome analysis reveals molecular mechanisms and indications of bupleuri radix.Frontiers in pharmacology · 2022Article
- Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma.Biomedicines · 2021Article
- LPCAT1 overexpression promotes the progression of hepatocellular carcinoma.Cancer cell international · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the continual discovery of promising new cancer targets, drug discovery is often hampered by the poor druggability of these targets. As such, repurposing FDA-approved drugs based on cancer signatures is a useful alternative to cancer precision medicine. Here, we adopted an in silico approach based on large-scale gene expression signatures to identify drug candidates for lung cancer metastasis. Our clinicogenomic analysis identified GALNT14 as a putative driver of lung cancer metastasis, leading to poor survival. To overcome the poor druggability of GALNT14 in the control of metastasis, we utilized the Connectivity Map and identified bortezomib (BTZ) as a potent metastatic inhibitor, bypassing the direct inhibition of the enzymatic activity of GALNT14. The antimetastatic effect of BTZ was verified both in vitro and in vivo. Notably, both BTZ treatment and GALNT14 knockdown attenuated TGFβ-mediated gene expression and suppressed TGFβ-dependent metastatic genes. These results demonstrate that our in silico approach is a viable strategy for the use of undruggable targets in cancer therapies and for revealing the underlying mechanisms of these targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.